Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer
The conclusion is that tislelizumab combination therapy is a cost-effective first-line treatment option for nsq-NSCLC patients in China.
Authors
- Ruxu You (ORCID: https://orcid.org/0000-0003-3057-4462)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-1090-6001)
- Jinyu Liu (ORCID: https://orcid.org/0000-0003-0114-0905)
- Luwen Shi
- Lin Wang (ORCID: https://orcid.org/0009-0001-0933-0220)
- Ting Liu (ORCID: https://orcid.org/0000-0001-7870-3783)
- Xihan Lin
Institutions
- Union Hospital (HK)
- Peking University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Immunotherapy
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1080/1750743x.2024.2433408
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57